Takeda Pharmaceutical stock

4502 · TSE · JPY

¥6,937.00Change from previous close: +0.16%Absolute change: +¥11.00

Close · November 16, 2026

Price history

+58.67% over the period

1 year: from ¥4,372.00 (November 17, 2025) to ¥6,937.00 (November 16, 2026), +58.67%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026¥6,937.00
October 30, 2026¥6,651.00
September 30, 2026¥5,780.00
August 31, 2026¥5,765.00
July 31, 2026¥5,513.00
June 30, 2026¥5,155.00
May 29, 2026¥5,118.00
April 30, 2026¥5,270.00
March 31, 2026¥5,664.00
February 27, 2026¥5,819.00
January 30, 2026¥5,242.00
December 30, 2025¥4,835.00
November 28, 2025¥4,506.00
November 17, 2025¥4,372.00

At a glance

  • The company

    Researches, develops, manufactures and markets pharmaceutical products in gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines and neuroscience

  • Latest results

    Quarter to September 30, 2026 · EPS ¥120.88 (estimate ¥45.70)

TickerLandia's take on Takeda Pharmaceutical

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low¥4,172.00
52-wk high¥6,989.00

−0.74% from the 52-week high

Analysts · 16 analysts

Average target¥6,815.81−1.75% vs. price

Buy 11 · Hold 5 · Sell 0 · Buy

TickerLandia Fingerprint: Takeda Pharmaceutical

Compared with similar companies: very strong momentum, very high dividend, and very low financial strength.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Takeda Pharmaceutical is pricier than similar companies

Takeda Pharmaceutical's P/E (trailing 12 months): 253.2, +515% against the median of a group of 11 similar companies (41.1).

Compared with 11 similar companies

Takeda Pharmaceutical's metrics compared with similar companies
MetricTakeda PharmaceuticalPosition in the groupBand
P/E (trailing 12 months)253.2High
Forward P/E40.1Middle
Operating margin16.6%Low
ROE0.6%Low
Debt/equity0.72High

Grey band: the middle half of the group; tick: the median; dot: Takeda Pharmaceutical. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥1.19T

Latest quarter · Q3 2026

Net income

¥192.43B

Latest quarter · Q3 2026

Quarterly net margin

16.2%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
¥10.48T
P/E
253.2
EPS
¥25.77
Volume
8.02M
Daily trading
€182.47M
Dividend yield
2.91%

How Takeda Pharmaceutical is changing

All results
  • Revenue grew 7.1% a year on average over the last 5 years

  • Operating margin fell from 15.4% to 13.5%

  • Profitable in 4 of 5 fiscal years

Returns

Takeda Pharmaceutical returns with dividends

¥1,000 invested in Takeda Pharmaceutical 5 years ago, on November 16, 2021, would be worth ¥2,633 today with dividends reinvested: +163.35% in total, +21.37% per year. On price alone it would be ¥2,125 (+112.47%).

PeriodTakeda PharmaceuticalNikkei 225¥1,000 becomes
1 month+11.47%−6.39%¥1,115
6 months+31.46%−0.42%¥1,315
Year to date+43.47%+21.48%¥1,435
1 year+64.32%+21.52%¥1,643
3 years+89.53%+82.95%¥1,895
5 years+163.35%+105.15%¥2,633
10 years+124.93%+242.35%¥2,249

Over the last 6 months it has done better than 71% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. Nikkei 225: price only. Calculate your investment

The chart in detail

Takeda Pharmaceutical: technical analysis

Takeda Pharmaceutical is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 16.9% below its all-time closing high (¥8,350.00, June 5, 2007).

Trend
Upward
RSI (14 sessions)
68
Between 30 and 70
vs 200-session average
+23.60%

Active signals

  • New 52-week high.

Support and resistance

Price areas where Takeda Pharmaceutical has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price¥6,937.00
  3. Support¥6,031.50−13.05%2 touches, last on September 24, 2026
  4. Support¥5,890.20−15.09%5 touches, last on September 3, 2026
  5. Support¥5,542.80−20.10%5 touches, last on October 5, 2026

Volatility and risk

Over the last year it has moved little with the Nikkei 225.

Beta (1 year) vs Nikkei 225
−0.01
Volatility (60 sessions, annualised)
26.5%
Largest fall in the last year
−19.39%

Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Takeda Pharmaceutical: seasonality

Average monthly price change over 37 years

+1.7%Jan−0.2%Feb−0.9%Mar+1.3%Apr−0.0%May−0.5%Jun+1.5%Jul−0.3%Aug+0.9%Sep+0.1%Oct+1.0%Nov+0.6%Dec

Over the last 37 years, the strongest month for Takeda Pharmaceutical has been January: +1.69% on average, positive in 16 years out of 36. The weakest has been March: −0.86% on average, positive in 19 years out of 37. November, the current month, has been positive in 21 years out of 36 (+1.04% on average).

Show chart data
MonthAverageMedianPositive years
January+1.69%−0.63%16 of 36
February−0.21%+0.57%20 of 37
March−0.86%+0.13%19 of 37
April+1.27%+0.65%19 of 37
May−0.05%+0.41%19 of 37
June−0.45%−0.27%16 of 37
July+1.52%+1.86%21 of 37
August−0.35%0.00%18 of 37
September+0.90%+0.38%20 of 37
October+0.14%+0.70%21 of 37
November+1.04%+0.85%21 of 36
December+0.61%+1.00%22 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Takeda Pharmaceutical and its competitors

Nearly half of the sales of this Japanese drugmaker are generated in the United States, which accounts for 48.0% of revenue, while Europe and Canada add 25.4% and Japan 9.6%. The company researches, develops, manufactures and markets pharmaceutical products, and it also out-licenses them to other companies. Its portfolio covers gastroenterology, neuroscience and oncology, with brands such as Entyvio, Adcetris, Trintellix and Vyvanse, along with the QDENGA brand.

Headquarters
Chuo, Japan
Employees
47,029
Founded
1781
Chief executive
Julie Kim
Takeda Pharmaceutical and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Takeda Pharmaceutical4502$65.5B16.6%253.2+31.46%
Sun Pharmaceutical IndustriesSUNPHARMA$47.86B23.3%41.1+3.02%
Jiangsu Hengrui Pharmaceuticals600276$47.82B27.4%35.9−11.06%
Divi's LaboratoriesDIVISLAB$32.23B34.0%90.6+63.89%
Hansoh Pharmaceutical Group3692$26.6B37.3%28.4−3.58%
Torrent PharmaceuticalsTORNTPHARM$18.85B22.2%78.9+6.48%

Same industry or related industries, similar size. Compare Takeda Pharmaceutical with its competitors · Full profile